Overnight Closed Loop Study in U.S.

Subjects that have met eligibility criteria will undergo treatment with the hybrid closed loop system under various experimental conditions.There is no statistically powered study hypothesis testing.

The investigational centers will be encouraged to include subjects of different ethnicities including Hispanic, Native American, and African-American.

The study is anticipated to last no more than 12 months from investigational center initiation to finalization of all data entry and monitoring procedures. Subjects are expected to participate for approximately 1- 2 months.

Inclusion criteria

• Subject is 2-75 years of age at time of screening
• A clinical diagnosis of type 1 diabetes as determined by either medical record or source documentation from qualified individual to make medical diagnosis

Exclusion criteria

that are Based on Demands of In-Clinic Study Procedures :

• Pump therapy for greater than 6 months with use of real time CGM for any period of time (ie. one day) 3 months prior to screening
• Adequate venous access as assessed by investigator or appropriate staff
• Subject should have an established insulin carbohydrate and insulin sensitivity ratio.
• Subject reports at the time of screening that their average fasting glucose is 60 mg/dL - 200 mg/dL
• Subject reports at the time of screening that their average total daily insulin dose is 15 units - 110 units. (Insulin pump memory for this information may be used)